Coya Therapeutics COYA
NASDAQ COYA
$4.86 +0.00 (+0.00%)
As of: Aug 21, 2026 · 3:59 PM EDT

Coya Therapeutics (COYA) Convertible Debt (2022)

Coya Therapeutics (COYA) posted Convertible Debt of $13.0 million for Q4 2022.

Coya Therapeutics (COYA) Convertible Debt (2022) Analysis & Trends

Coya Therapeutics has reported Convertible Debt for 1 years, with the latest figure at $13.0 million in Q4 2022.

  • Quarterly Convertible Debt changed N/A year-over-year to $13.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $13.0 million (changed N/A YoY) and the FY2022 annual result came in at $13.0 million, changed N/A from the prior year.
  • Convertible Debt was little changed at $13.0 million in Q4 2022 per COYA's latest filing.
  • Over five years, Convertible Debt peaked at $13.0 million in Q4 2022 and troughed at $13.0 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Coya Therapeutics 113.53 Mn 70.33 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 12.97 Mn